Eisai and Biogen's Alzheimer’s drug sparks hot debate over benefits as risks like brain bleeding emerge
Two recent deaths during clinical tests had significant comorbidity causes and risk factors, but recent data still indicates that the companies’ Alzheimer’s drug comes with serious adverse effects.
By Robert Langreth, bloomberg
Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Axsome races for Alzheimer's agitation approval
For subscribers
